Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Thomas Fuller | Lightrocket | Getty Images Replimune plans to resubmit its melanoma drug to the Food and Drug Administration
Read More
Sunday, July 26, 2026
Latest News:
- Wall Street Left This Company for Dead. Then It Became the Trade of the Decade.
- Prediction markets and their opponents are spending more to influence Congress in 2026
- Stocks making the biggest moves premarket: Netflix, SpaceX, Alphabet and more
- Alphabet and Tesla test Wall Street’s patience as AI spending overshadows growth
- Jamie Dimon says markets underestimate risks and he wouldn’t buy stocks or Treasurys at
resubmit